{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:49:41Z","timestamp":1791442181975,"version":"4.3.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA077598"],"award-info":[{"award-number":["P30 CA077598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department Of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-2-0025"],"award-info":[{"award-number":["W81XWH-22-2-0025"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA304954"],"award-info":[{"award-number":["R50CA304954"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Approximately one-third of men with metastatic prostate cancer die from causes other than prostate cancer. Little is known about the long-term outcomes of men with metastatic prostate cancer, in particular those who do not develop androgen pathway resistance. The objective of this study is to describe those with long-term survival and disease response to initial therapy and their clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-institution, retrospective study of patients with metastatic hormone-sensitive prostate cancer diagnosed prior to January 1, 2019 and alive as of December 31, 2024. Clinical and demographic features are described at baseline and follow-up, with outcomes after treatment cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings and limitations<\/jats:title>\n                    <jats:p>One hundred and forty-five patients were included with a median age at diagnosis of 61\u2009years. Fifty-one patients (35.2%) had metastatic disease at diagnosis, and 108 (74.5%) had bone metastases at the time of metastatic disease. The median follow-up from the date of metastatic disease was 8.4\u2009years. Eighty-nine (61.4%) patients continued to have disease response to initial therapy after a median of 8.8\u2009years. Thirty-two patients stopped therapy, and of those, 25 recovered testosterone, with 11 patients continuing to have an undetectable prostate-specific antigen (8% of total cohort and 34% of those who stopped therapy).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical implications<\/jats:title>\n                    <jats:p>In this cohort, most patients did not have further progression of disease, and 8% of patients had durable treatment-free remissions. Further research is needed on treatment cessation in men with exceptional responses to androgen deprivation therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag375","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:01:49Z","timestamp":1790164909000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-402X","authenticated-orcid":false,"given":"Monica","family":"Meeks","sequence":"first","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4592-2065","authenticated-orcid":false,"given":"Yasaman","family":"Iranmanesh","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9593-9489","authenticated-orcid":false,"given":"Hyunsoo","family":"Song","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-4833","authenticated-orcid":false,"given":"Amanda L","family":"Blackford","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7178-2345","authenticated-orcid":false,"given":"Arya","family":"Rasouli","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-3342","authenticated-orcid":false,"given":"Alex","family":"Baras","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-515X","authenticated-orcid":false,"given":"Samuel R","family":"Denmeade","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-5100","authenticated-orcid":false,"given":"Mark C","family":"Markowski","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J","family":"Paller","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-1215","authenticated-orcid":false,"given":"Michael A","family":"Carducci","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-3851","authenticated-orcid":false,"given":"Emmanuel S","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"University of Minnesota Masonic Cancer Center, , Minneapolis, Minnesota, 55455,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A","family":"Eisenberger","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-4110","authenticated-orcid":false,"given":"Catherine H","family":"Marshall","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine Department of Oncology, , Baltimore, Maryland, 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026100801535932300_oyag375-B1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1055-9965.EPI-22-1038","article-title":"Estimating the number of men living with metastatic prostate cancer in the United States","volume":"32","author":"Devasia","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026100801535932300_oyag375-B2","doi-asserted-by":"crossref","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw Open."},{"key":"2026100801535932300_oyag375-B3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026100801535932300_oyag375-B4","doi-asserted-by":"crossref","first-page":"S1627","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"LBA6 phase III trial of [177Lu]Lu-PSMA-617 combined with ADT\u2009+\u2009ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol."},{"key":"2026100801535932300_oyag375-B5","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.3390\/cancers13194951","article-title":"Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the Real-World patients in the United States","volume":"13","author":"Swami","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026100801535932300_oyag375-B6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12032-018-1110-y","article-title":"Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases","volume":"35","author":"Nieder","year":"2018","journal-title":"Med Oncol."},{"key":"2026100801535932300_oyag375-B7","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2025.43.16_suppl.5002","article-title":"Prognostic significance of PSA &gt; 0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): a multinational real-world analysis of the IRONMAN registry","volume":"43","author":"Ong","year":"2025","journal-title":"JCO"},{"key":"2026100801535932300_oyag375-B8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa2603878","article-title":"Perioperative apalutamide in high-risk localized prostate cancer","volume":"395","author":"Taplin","year":"2026","journal-title":"New Eng J Med"},{"key":"2026100801535932300_oyag375-B9","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.annonc.2025.08.004","article-title":"Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial","volume":"36","author":"Tripathi","year":"2025","journal-title":"Ann Oncol"},{"key":"2026100801535932300_oyag375-B10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CGC.2003.n.011","article-title":"Ten-year survival in patients with metastatic prostate cancer","volume":"2","author":"Tangen","year":"2003","journal-title":"Clin Prostate Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag375\/71352886\/oyag375.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag375\/71352886\/oyag375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag375\/71352886\/oyag375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:54:07Z","timestamp":1791438847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag375\/8832334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag375","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,23]]},"article-number":"oyag375"}}